Tarsus Pharmaceuticals, Inc. (TARS)
Market Cap | 1.04B |
Revenue (ttm) | 42.56M |
Net Income (ttm) | -148.21M |
Shares Out | 37.78M |
EPS (ttm) | -4.73 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 844,634 |
Open | 28.32 |
Previous Close | 28.24 |
Day's Range | 27.25 - 28.49 |
52-Week Range | 12.57 - 42.50 |
Beta | 1.10 |
Analysts | Strong Buy |
Price Target | 50.83 (+84.5%) |
Earnings Date | Aug 8, 2024 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to addr... [Read more]
Financial Performance
In 2023, TARS's revenue was $17.45 million, a decrease of -32.42% compared to the previous year's $25.82 million. Losses were -$135.89 million, 118.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is $50.83, which is an increase of 84.50% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/0/u/conf14-2452682.jpg)
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...
![](https://cdn.snapi.dev/images/v1/u/v/press2-2422878.jpg)
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...
![](https://cdn.snapi.dev/images/v1/9/y/press2-2419237.jpg)
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients
![](https://cdn.snapi.dev/images/v1/n/y/conf14-2404541.jpg)
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...
![](https://cdn.snapi.dev/images/v1/e/w/press17-2385264.jpg)
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...
![](https://cdn.snapi.dev/images/v1/c/l/conf15-2309658.jpg)
Tarsus to Participate at Upcoming Investor Conferences
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...
![](https://cdn.snapi.dev/images/v1/c/8/press7-2308396.jpg)
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease
![](https://cdn.snapi.dev/images/v1/m/r/press17-2302984.jpg)
Tarsus Announces Pricing of $100.0 Million Public Offering
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new te...
![](https://cdn.snapi.dev/images/v1/z/g/press15-2302461.jpg)
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...
![](https://cdn.snapi.dev/images/v1/x/f/press1-2295234.jpg)
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four m...
![](https://cdn.snapi.dev/images/v1/h/a/press13-2288311.jpg)
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis TP-05 demonstrated tolerability and statistically significant ...
![](https://cdn.snapi.dev/images/v1/l/d/conf2-2284796.jpg)
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
![](https://cdn.snapi.dev/images/v1/l/m/press13-2254313.jpg)
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
![](https://cdn.snapi.dev/images/v1/a/h/press4-2190904.jpg)
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated TP-03 demonstrated sta...
![](https://cdn.snapi.dev/images/v1/6/o/press19-2150905.jpg)
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis
![](https://cdn.snapi.dev/images/v1/n/s/conf1-2134720.jpg)
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
![](https://cdn.snapi.dev/images/v1/c/o/press18-2051116.jpg)
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...
![](https://cdn.snapi.dev/images/v1/y/j/conf12-2043925.jpg)
Tarsus to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
![](https://cdn.snapi.dev/images/v1/l/u/press1-2035928.jpg)
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available v...
![](https://cdn.snapi.dev/images/v1/d/b/press17-2018317.jpg)
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enro...
![](https://cdn.snapi.dev/images/v1/8/i/press15-2000594.jpg)
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...
![](https://cdn.snapi.dev/images/v1/n/b/press12-1997597.jpg)
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...
![](https://cdn.snapi.dev/images/v1/c/t/press18-1985881.jpg)
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S.
![](https://cdn.snapi.dev/images/v1/k/x/conf20-1930014.jpg)
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
![](https://cdn.snapi.dev/images/v1/g/k/conf12-1920615.jpg)
Tarsus to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...